BLACKSBURG, Va.–(BUSINESS WIRE)– #ACG2026–NImmune reports ACG 2026 data supporting omilancor and NIM-1324 in hard-to-treat IBD, highlighting LANCL2 and its TITAN-X AI platform.
BLACKSBURG, Va.–(BUSINESS WIRE)– #ACG2026–NImmune reports ACG 2026 data supporting omilancor and NIM-1324 in hard-to-treat IBD, highlighting LANCL2 and its TITAN-X AI platform.